Immunic Historical Cash Flow
| IMUX Stock | USD 1.24 0.04 3.33% |
Analysis of Immunic cash flow over time is an excellent tool to project Immunic future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 60.1 M or Other Cashflows From Financing Activities of 171 K as it is a great indicator of Immunic ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Immunic latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Immunic is a good buy for the upcoming year.
Immunic |
About Immunic Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Immunic balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Immunic's non-liquid assets can be easily converted into cash.
Immunic Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Investments
Securities or assets acquired for generating income or appreciating in value, not used in daily operations.Most accounts from Immunic's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Immunic current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.At this time, Immunic's Change In Working Capital is fairly stable compared to the past year. Capital Expenditures is likely to rise to about 496.2 K in 2024, despite the fact that Change In Cash is likely to grow to (57.1 M).
Immunic cash flow statement Correlations
Click cells to compare fundamentals
Immunic Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Immunic cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 16.3M | 98.1M | (40.6M) | 19.9M | (60.1M) | (57.1M) | |
| Stock Based Compensation | 6.5M | 2.7M | 5.9M | 7.9M | 7.1M | 4.4M | |
| Free Cash Flow | (28.6M) | (46.3M) | (83.3M) | (65.3M) | (71.2M) | (67.6M) | |
| Change In Working Capital | (1.4M) | (2.4M) | (9.3M) | 9.5M | 15.0M | 15.8M | |
| Begin Period Cash Flow | 13.1M | 29.4M | 127.5M | 86.9M | 106.7M | 60.1M | |
| Other Cashflows From Financing Activities | (270K) | (146K) | 92K | 56.2M | 180K | 171K | |
| Depreciation | 50K | 39K | 85K | 77K | 111K | 105.5K | |
| Other Non Cash Items | 1.5M | (2.5M) | 8.6M | 37.7M | 523K | 496.9K | |
| Capital Expenditures | 55K | 146K | 67K | 112K | 334K | 496.2K | |
| Total Cash From Operating Activities | (28.5M) | (46.1M) | (83.2M) | (65.1M) | (70.8M) | (67.3M) | |
| Net Income | (34.9M) | (44.0M) | (92.9M) | (120.4M) | (93.6M) | (88.9M) | |
| Total Cash From Financing Activities | 34.9M | 144.4M | 42.8K | 95.8K | 1.0M | 981.4K | |
| End Period Cash Flow | 29.4M | 127.5M | 86.9M | 106.7M | 46.7M | 64.0M | |
| Sale Purchase Of Stock | 34.9M | 144.4M | 92K | 182K | 129K | 122.6K | |
| Total Cashflows From Investing Activities | 10.5M | (146K) | (67K) | (9.7M) | (8.8M) | (8.3M) | |
| Cash And Cash Equivalents Changes | 16.9M | 98.2M | (40.5M) | 20.9M | 24.0M | 25.2M | |
| Cash Flows Other Operating | (2.2M) | (2.8M) | (12.8M) | 7.5M | 6.7M | 7.1M | |
| Change To Netincome | 7.7M | 219K | 18.9M | 45.7M | 52.5M | 55.1M | |
| Change To Liabilities | 865K | 414K | 3.5M | 2.0M | 2.3M | 2.5M | |
| Investments | 10.5M | (146K) | (67K) | (9.7M) | 9.5M | 9.9M | |
| Change To Operating Activities | (897K) | (3.4M) | (9.5M) | 8.7M | 10.0M | 10.5M | |
| Issuance Of Capital Stock | 35.2M | 144.4M | 42.7M | 95.6M | 853K | 810.4K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immunic Stock Analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.